Part 18 of our Bridging the Gap Series (Summary of the webinar session held in May 2025) Access to advanced therapies that can fundamentally alter disease trajectories is one of the most pressing frontiers in healthcare. Among them, cell and gene therapies offer unprecedented hope for millions, especially those grappling with rare, chronic, or previously untreatable conditions. […]
View Blog
Part 17 of our Bridging the Gap Series (Summary of the webinar session held in April 2025) Across the globe, access to life-saving cell and gene therapies like chimeric antigen receptor (CAR) T-cell therapy remains largely limited to wealthier nations and well-resourced health systems. While the clinical outcomes of these therapies can be extraordinary—offering cures for certain […]
View Blog
Part 16 of our Bridging the Gap Series (Summary of the webinar session held in March 2025) Mesenchymal stem cells (MSCs) have long shown promise in regenerative medicine, with the potential to treat everything from heart disease to autoimmune conditions. But for decades, MSC therapies struggled to move beyond early-phase clinical trials and regional approvals. That changed […]
View Blog
Part 15 of our Bridging the Gap Series (Summary of the webinar session held in February 2025) Access to cutting-edge gene therapy treatments remains a major challenge, particularly in low- and middle-income countries (LMICs). While these therapies hold the potential to cure life-threatening conditions such as hemophilia, HIV, and sickle cell disease, their availability today is generally […]
View Blog
Part 14 of our Bridging the Gap Series (Summary of the webinar session held in january 2025) In early January 2025, Bridging the Gap panelists George Eastwood and Patrick Hanley visited Washington, D.C., to advocate for increased support and funding for life-saving cell and gene therapies. During its first year, the Bridging the Gap Webinar Series, sponsored […]
View Blog
Part 13 of our Bridging the Gap Series (Summary of the webinar session held in December 2024) Groundbreaking advancements in cell and gene therapies offer unprecedented hope for patients battling cancers, autoimmune diseases, and genetic disorders. Yet, transforming academic breakthroughs into therapies ready for patients is a complex and challenging journey. Issues such as scalable manufacturing processes, […]
View Blog
Part 1 of our Cryo Cold Chain Management for CGT Series With a projected rate of 10-20 product approvals per year, the global cell and gene therapy (CGT) industry is rapidly evolving. The clinical pipeline delivers a promise to the patient population with unmet medical needs ranging from oncology to autoimmune diseases and rare genetic conditions. In […]
View Blog
Part 12 of our Bridging the Gap Series (Summary of the webinar session held in November 2024) Pictured in photo: Sickle cell warrior Jimi Olaghere climbed Mt. Kilimanjaro after receiving advanced gene therapy. The incredible potential of gene therapies like chimeric antigen receptor T-cell therapy (CAR-T) and clustered regularly interspaced short palindromic repeats (CRISPR) to cure genetic diseases […]
View Blog
Recap of 1 Year of our Bridging the Gap Series In November 2024, Azenta Life Sciences celebrated the one-year anniversary of its “Bridging the Gap” webinar series, an insightful resource in cell and gene therapy (CGT) education, co-sponsored by the Emily Whitehead Foundation. Over the past year, this series has become a resource for industry experts and […]
View Blog
Part 11 of our Bridging the Gap Series (Summary of the webinar session held in October 2024) In the rapidly advancing world of cell and gene therapy, we are witnessing groundbreaking innovations that have the potential to cure once-incurable diseases like cancer and sickle cell. Yet, as these transformative therapies emerge, a troubling reality persists: access to […]
View Blog